Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: A multicenter randomized phase III trial

J. Liang, N. Bi, S. Wu, M. Chen, C. Lv, L. Zhao, A. Shi, W. Jiang, Y. Xu, Z. Zhou, W. Wang, D. Chen, Z. Hui, J. Lv, H. Zhang, Q. Feng, Z. Xiao, X. Wang, L. Liu, T. ZhangL. Du, W. Chen, Y. Shyr, W. Yin, J. Li, J. He, L. Wang

研究成果: Article同行評審

72 引文 斯高帕斯(Scopus)

摘要

Background: The optimal chemotherapy regimen administered currently with radiation in patients with stage III non-small cell lung cancer (NSCLC) remains unclear. A multicenter phase III trial was conducted to compare the efficacy of concurrent thoracic radiation therapy with either etoposide/cisplatin (EP) or carboplatin/paclitaxel (PC) in patients with stage III NSCLC. Patients and methods: Patients were randomly received 60-66 Gy of thoracic radiation therapy concurrent with either etoposide 50 mg/m2 on days 1-5 and cisplatin 50 mg/m2 on days 1 and 8 every 4 weeks for two cycles (EP arm), or paclitaxel 45 mg/m2 and carboplatin (AUC 2) on day 1 weekly (PC arm). The primary end point was overall survival (OS). The study was designed with 80% power to detect a 17% superiority in 3-year OS with a type I error rate of 0.05. Results: A total of 200 patients were randomized and 191 patients were treated (95 in the EP arm and 96 in the PC arm). With a median follow-up time of 73 months, the 3-year OS was significantly higher in the EP arm than that of the PC arm. The estimated difference was 15.0% (95% CI 2.0%-28.0%) and P value of 0.024. Median survival times were 23.3 months in the EP arm and 20.7 months in the PC arm (log-rank test P=0.095, HR 0.76, 95%CI 0.55-1.05). The incidence of Grade ≥ 2 radiation pneumonitis was higher in the PC arm (33.3% versus 18.9%, P=0.036), while the incidence of Grade ≥ 3 esophagitis was higher in the EP arm (20.0% versus 6.3%, P=0.009). Conclusion: EP might be superior to weekly PC in terms of OS in the setting of concurrent chemoradiation for unresectable stage III NSCLC. Trial registration ID: NCT01494558.

原文English
頁(從 - 到)777-783
頁數7
期刊Annals of Oncology
28
發行號4
DOIs
出版狀態Published - 2017 四月 1

All Science Journal Classification (ASJC) codes

  • 血液學
  • 腫瘤科

指紋

深入研究「Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: A multicenter randomized phase III trial」主題。共同形成了獨特的指紋。

引用此